| Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? |
30 |
| Are new antiretroviral treatments increasing the risks of clinical obesity? |
23 |
| How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP |
15 |
| The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals |
15 |
| Establishment of latent HIV-1 reservoirs: what do we really know? |
13 |
| Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs |
9 |
| Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review |
8 |
| Crowdsourcing and community engagement: a qualitative analysis of the 2BeatHIV contest |
7 |
| A landscape analysis of HIV cure-related clinical trials and observational studies in 2018 |
6 |
| Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access |
6 |
| Traversing the cascade: urgent research priorities for implementing the 'treat all' strategy for children and adolescents living with HIV in sub-Saharan Africa |
6 |
| What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study |
6 |
| HIV-associated cognitive performance and psychomotor impairment in a Thai cohort on long-term cART |
5 |
| A decentralised, multidisciplinary model of care facilitates treatment of hepatitis C in regional Australia |
5 |
| The contribution of observational studies in supporting the WHO 'treat all' recommendation for HIV/AIDS |
5 |
| Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries |
4 |
| Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis |
4 |
| Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Delta 32 heterozygous and HLA-B57 genotype |
4 |
| HIV rapid diagnostic testing by lay providers in a key population-led health service programme in Thailand |
4 |
| Most new HIV infections, vertical transmissions and AIDS-related deaths occur in lower-prevalence countries |
3 |
| What risk of death would people take to be cured of HIV and why? A survey of people living with HIV |
3 |
| Markers of subclinical atherosclerotic disease in HIV-infected individuals |
3 |
| Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation |
3 |
| Substance use and universal access to HIV testing and treatment in sub-Saharan Africa: implications and research priorities |
3 |
| Mental health and HIV: research priorities related to the implementation and scale up of 'treat all' in sub-Saharan Africa |
3 |
| Implementation of hepatitis C cure in Australia: one year on |
3 |
| Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission |
3 |
| The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C |
3 |
| Investigating the role of stigma on fertility desire among HIV-positive women in Bangkok, Thailand: a qualitative study |
3 |
| Treatment outcomes and factors associated with mortality among individuals with both TB and HIV in the antiretroviral era in Thailand |
2 |
| Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research |
2 |
| Maximising the global health impact of future HIV cure-related interventions through advance planning |
2 |
| The impact of HIV prevalence, conflict, corruption, and GDP/capita on treatment cascades: data from 137 countries |
2 |
| Ethical challenges in developing an educational video to empower potential participants during consent processes in HIV cure research in South Africa |
2 |
| Impact of an educational video as a consent tool on knowledge about cure research among patients and caregivers at HIV clinics in South Africa |
2 |
| Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals |
2 |
| IeDEA-WHO Research-Policy Collaboration: contributing real-world evidence to HIV progress reporting and guideline development |
2 |
| HIV-1 elite controllers: an immunovirological review and clinical perspectives |
2 |
| Statistical analysis of single-copy assays when some observations are zero |
2 |
| Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study |
2 |
| Revisiting the 'sterilising cure' terminology: a call for more patient-centred perspectives on HIV cure-related research |
2 |
| Knowledge, attitude and practice of medical laboratory practitioners in the fight against Ebola virus disease |
2 |
| Effect of calcium and vitamin D supplementation on bone mineral accrual among HIV-infected Thai adolescents with low bone mineral density |
2 |
| Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India |
1 |
| Dermatological conditions associated with HIV medication in a cohort of Greek patients initiating antiretroviral therapy: 1988-2013 |
1 |
| Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia |
1 |
| Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency |
1 |
| HIV self-testing among men who have sex with men in China: a qualitative implementation research study |
1 |
| Analysis of ex vivo HIV-1 infection in a controller-discordant couple |
1 |
| Careful consideration when responding to new data: dolutegravir and pregnancy |
1 |
